360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

JANUMET

Type: Product

Name: JANUMET

First reported May 23 2013 - Updated May 23 2013 - 1 reports

New Delhi (India)

Patent row: Delhi HC to hear diabetes drug case

New Delhi: The patent battle between US pharmaceuticals major Merck Sharp and Dohme (MSD) and Indian firm Glenmark Pharmaceuticals over the sale of diabetes drug Januvia comes up for hearing in the Delhi High Court on Thursday. Indian pharma company Glenmark ... [Published IBNLive India News - May 23 2013]

Entities: Merck & Co Inc, Diabetes, New Delhi (India), SITAGLIPTIN

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Eli Lilly & Company

The 5 Highest-Paying Dividend Stocks in Big Pharma

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today.Any investor looking for the highest-paying dividend stocks would do well to start in Big Pharma, where many of the top picks offer yields ... [Published Motley Fool - May 22 2013]

Entities: Dividend, Eli Lilly & Company, AbbVie

First reported May 21 2013 - Updated May 22 2013 - 3 reports

SITAGLIPTIN

A Diabetes Drug Dispute

As life-style diseases become important in India, so will patent disputes over drugs. We have just had one between Merck Sharp and Dohme Corporation (MSD) and Glenmark, where MSD sought interim relief, refused by Delhi High Court. In 2007, MSD obtained ... [Published Economic Times - May 22 2013]

Entities: SITAGLIPTIN, Patent, Glenmark Pharmaceuticals Ltd

First reported May 21 2013 - Updated May 21 2013 - 1 reports

IMS Health Inc

Patented drugs find it tough to get branded

own the best-selling medicine brands in India, according to market research reports released last month. However, their marquee brands are almost always their heritage brands, with their recent drug discoveries never making it to top rankings.Corex, Augmentin, ... [Published Sify - May 21 2013]

Entities: Patent, Drugs, Galvus, IMS Health Inc, JANUMET

First reported May 20 2013 - Updated May 21 2013 - 2 reports

Potential Lawsuit: Diabetes Medication Lawsuits

Home Page >> Potential Lawsuit >> Diabetes Medication Side Effects LawsuitsWere you looking for Actos or Byetta or Januvia or Victoza Side Effects lawsuits?The use of some diabetes medications has been linked in recent studies to an increased ... [Published Lawyers & Settlements - May 21 2013]

Entities: Diabetes, Byetta, Victoza, Pancreatic Cancer

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Merck & Co Inc

Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)

Merck & Co., Inc. (MRK) UBS Global Healthcare Conference Call May 20, 2013 10:30 AM ETMarc Goodman - UBSSo good morning everybody, thanks for joining us for the conference. I am Marc Goodman, I cover large cap pharma and specialty pharma for UBS. And ... [Published Seeking Alpha - May 20 2013]

Entities: Merck & Co Inc, Patent, Mergers & Acquisitions, SITAGLIPTIN

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Johnson & Johnson

2 Red Flags for Merck's Type 2 Diabetes Blockbuster

In the following video, Fool contributor Maxxwell Chatsko provides an update on the outlook of Merck's best-selling type 2 diabetes drug franchise of Januvia/Janumet. While the franchise reeled in about $5.75 billion in 2012, it stumbled out of the gates ... [Published Motley Fool - May 15 2013]

Entities: Diabetes Type II, Johnson & Johnson, JANUMET, Bioprocessing

First reported May 10 2013 - Updated May 10 2013 - 1 reports

The First Step in Treating Type 2 Diabetes

Your own personalized stock watchlist!It's a 100% FREE Motley Fool service...According to the American Diabetes Association, 8.3% of the population has diabetes, making it a pretty common ailment. A vast majority of those cases fall into the type 2 class ... [Published Motley Fool Discussion Boards - May 10 2013]

Entities: Metformin, Diabetes Type II, Blood Glucose

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Merck & Co., Inc. (MRK), Novo Nordisk A/S (ADR) (NVO): Who Should You Buy?

Recently, I have focused in on some companies that play a major role in diabetic’s lives like mine. The financial implications of this disease are astounding, and have presented what seems to be a great opportunity for investors. Today, I will discuss ... [Published InsiderMonkey.com - May 08 2013]

Entities: SITAGLIPTIN, NOVO NORDISK A/S, Merck & Co Inc

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Merck Stock Drops After Q1 Sales Miss, Guidance Cut

Posted 11:11 AM ETShares of Merck (MRK) were down more than 2% in the stock market early Wednesday after the big pharma reported an ugly quarter and cut its guidance.Merck reported sales of $10.67 billion, down 9% from the year-earlier quarter and $500 ... [Published Investors Business Daily - May 01 2013]

Entities: Merck & Co Inc, JANUMET, Pfizer Inc, Mark Schoenebaum

First reported Apr 30 2013 - Updated May 01 2013 - 7 reports

HEALTH Full Page Merck's Januvia diabetes drug lags, 2013 forecast cut

- Merck & Co Inc reported disappointing initial-quarter sales on a surprising downturn for its Januvia diabetes medicine, the company's biggest product and usual earnings driver, and the drugmaker cut its profit forecast for the full year.Shares of Merck ... [Published The Oregon Herald - May 01 2013]

Entities: SITAGLIPTIN, Merck & Co Inc, Drugs, Diabetes, JANUMET

First reported Apr 29 2013 - Updated Apr 30 2013 - 2 reports

Pfizer, Merck team up on diabetes drug

New York - Pfizer and Merck said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, including Merck's blockbuster Januvia.The Pfizer medicine belongs to a new ... [Published Daily News South Africa - Apr 30 2013]

Entities: Pfizer Inc, Merck & Co Inc, SITAGLIPTIN

Quotes

"Glenmark has already responded to the appeal within the time fixed by the court" said a Glenmark spokesperson

MSD-Glenmark case to provide clarity on multiple patenting [Published Individual.com - May 22 2013]

"The companies will have to align with local conditions - be it (choosing) the right therapy (or ailment), affordable pricing, patient (contact) programmes or marketing tie-ups (for distribution). This will enable the brands to widen their reach and gain acceptance. Januvia and Galvus are perfect examples of patented brands that have been successful in India" says Hinduja

Patented drugs find it tough to get branded [Published Sify - May 21 2013]

"It's a practice that leases space [at dePoo]," Will said Thursday. "The meds are not property of the Lower Keys Medical Center. He's a member of our staff."

Police: Heart doctor steals meds [Published Marathon & Big Pine Free Press - May 17 2013]

...A paper published in Current Medical Research and Opinion in December 2009 (Vol. 25-No.12:2903-2913) entitled, "Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis" concludes that SMBG compared with non-SMBG is associated with a significantly improved glycaemic control in non-insulin treated patients with type-2...

LabStyle Innovations - Glucose Monitoring For The Mobile Age [Published Seeking Alpha - May 15 2013]

More Content

sort by: Date \| Relevance
Offer Update [Published TrustNet - May 24 2013]
LawyersandSettlements.com Provides Update on Di... [Published PRWeb - May 23 2013]
Patent row: Delhi HC to hear diabetes drug case [Published IBNLive India News - May 23 2013]
The 5 Highest-Paying Dividend Stocks in Big Pharma [Published Motley Fool - May 22 2013]
A Diabetes Drug Dispute [Published Economic Times - May 22 2013]
MSD-Glenmark case to provide clarity on multipl... [Published Individual.com - May 22 2013]
Patented drugs find it tough to get branded [Published Sify - May 21 2013]
MSD-Glenmark case to provide clarity on multipl... [Published Livemint.com - May 21 2013]
Potential Lawsuit: Diabetes Medication Lawsuits [Published Lawyers & Settlements - May 21 2013]
DrugRisk Update: FDA Investigating Pre-Cancerou... [Published PRWeb - May 20 2013]
Merck & Co., Inc. Management Presents at UBS Gl... [Published Seeking Alpha - May 20 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published Scottrade - May 20 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published FinanzNachrichten.de - May 20 2013]
Police: Heart doctor steals meds [Published Marathon & Big Pine Free Press - May 17 2013]
LabStyle Innovations - Glucose Monitoring For T... [Published Seeking Alpha - May 15 2013]
2 Red Flags for Merck's Type 2 Diabetes Blockbu... [Published Motley Fool - May 15 2013]
Merck & Co., Inc. (MRK): Big Payout, Little Fle... [Published InsiderMonkey.com - May 13 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published Motley Fool - May 11 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published Motley Fool Discussion Boards - May 11 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published EquityJungle - v0.1 - May 11 2013]
The First Step in Treating Type 2 Diabetes [Published Motley Fool Discussion Boards - May 10 2013]
Alleged Januvia Pancreatic Cancer Lawsuits Offe... [Published PRWeb - May 10 2013]
DrugRisk Update: Januvia Maker Agrees to Transf... [Published PRWeb - May 10 2013]
Pfizer Inc. (PFE), Johnson & Johnson (JNJ): The... [Published InsiderMonkey.com - May 09 2013]
Janumet XR and AffordRX.com Team Up to Offer Di... [Published PR.com Press Releases - May 09 2013]
Is the Golden Age of Blockbusters Over? [Published Motley Fool - May 09 2013]
DepoMed Management Discusses Q1 2013 Results - ... [Published Seeking Alpha - May 09 2013]
Merck & Co., Inc. (MRK), Novo Nordisk A/S (ADR)... [Published InsiderMonkey.com - May 08 2013]
The Ups and Downs of Diabetes [Published Motley Fool - May 08 2013]
This Biotech Stock Keeps Investors Patiently Wa... [Published Motley Fool - May 08 2013]

Blogs

sort by: Date \| Relevance
Merck Stock: Not a Safe Pick for Dividend Inves... [Published EquityJungle - v0.1 - May 11 2013] Filed under: Investing Big pharma isn't the first industry many investors envision when dreaming of the big profits to be made from health care stocks. While blockbuster drugs can propel the top big pharma companies to massive profits, these broad ...
Buzzworthy Catalysts Giving Juice to Dow 30 Hea... [Published Wall St. Cheat Sheet - Apr 07 2013] Pfizer ( NYSE:PFE ): Current price $29.09 Pfizer, Procter & Gamble ( NYSE:PG ), and Arm & Hammer owner Church & Dwight Co. ( NYSE:CHD ) all bought manufacturers of dietary supplements in 2012, and more such deals are expected, as companies gamble ...
4 Healthcare Stock Stories For Midweek Perusal [Published Wall St. Cheat Sheet - Apr 03 2013] Astex Pharmaceuticals ( NASDAQ:ASTX ): Current price $5.49 On Wednesday, Astex announced the acceptance of thirteen abstracts that cover internal and partner funded pipeline product data, for presentation at the American Association for Cancer Research ...
Pfizer Partners With Tetragenetics and 2 Dow Mo... [Published Wall St. Cheat Sheet - Apr 03 2013] Merck & Co. ( NYSE:MRK ): Current price $46.10 Merck Sharp and Dohme has brought a lawsuit against Mumbai-based Glenmark Pharmaceuticals in the Delhi High Court, claiming violation of its patent for blockbuster anti-diabetes drugs Januvia and Janumet, ...
Watchdog Wants FDA To Ban Some Diabetes Drugs [Published Pharmalot - Mar 26 2013] For the past month, a group of diabetes drugs have been under a microscope over concerns they cause not only pancreatitis, but also pre-cancerous cellular changes. Pancreatitis is actually not a new concern; the FDA issued alerts twice in recent years ...

Press Releases

sort by: Date \| Relevance
Janumet XR and AffordRX.com Team Up to Offer Di... [Published PR.com Press Releases - May 09 2013]